Today the FDA approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for patients age 16 years and older.
from FDA Press Releases RSS Feed https://ift.tt/353lX7g
via IFTTT
No comments:
Post a Comment